Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5075695 | 1.00 | OPRM1 (0.32) | OPRM1OPRD1MAPTPOLB | |
| SCHEMBL5078926 | 1.00 | OPRM1 (0.32) | OPRM1OPRD1MAPTPOLB | |
| SCHEMBL6903798 | 0.90 | OPRM1 (0.35) | OPRM1OPRD1 | |
| SCHEMBL6903028 | 0.90 | OPRM1 (0.35) | OPRM1OPRD1 | |
| SCHEMBL6905064 | 0.90 | OPRM1 (0.35) | OPRM1OPRD1 | |
| SCHEMBL7081162 | 0.88 | OPRM1 (0.34) | OPRM1OPRD1 | |
| SCHEMBL7081826 | 0.88 | OPRM1 (0.34) | OPRM1OPRD1 | |
| SCHEMBL7088878 | 0.88 | OPRM1 (0.34) | OPRM1OPRD1 | |
| SCHEMBL674830 | 0.84 | CYP2D6 (0.38) | OPRM1OPRD1 | |
| SCHEMBL6903343 | 0.84 | CYP3A4 (0.31) | OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1328269-B1 | ASSOCIATION OF A CB1 RECEPTOR ANTAGONIST AND SIBUTRAMIN FOR TREATING OBESITY | AVENTIS PHARMA SA (FR) | 2004-05-26 | — | — | EP | claimed |
| US-20080058381-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | AVENTIS PHARMA S.A. (FR) | 2008-03-06 | — | — | US | disclosed |
| US-20060258709-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | AVENTIS PHARMA S.A. (FR) | 2006-11-16 | — | — | US | disclosed |
| US-20050032773-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositons comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058381-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | CNR2, CNR1, GPR119 | OPRM1 37/4885OPRD1 54/4885MAPT 2194/4885 |
| US-20060258709-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | CNR2, CNR1, GPR119 | OPRM1 37/4885OPRD1 54/4885MAPT 2194/4885 |
| US-20050032773-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositons comprising them and their use in the treatment of obesity | CNR2, CNR1, GPR119 | OPRM1 20/4885OPRD1 49/4885MAPT 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.